發(fā)布時(shí)間：2018-06-20 15:58

  本文選題：芪參益氣滴丸 + 心脈通貼散��； 參考：《南京中醫(yī)藥大學(xué)》2017年博士論文

【摘要】：冠心病是目前臨床上的常見(jiàn)病、多發(fā)病,近年來(lái)其死亡率不斷上升,2014年中國(guó)心血管病死亡(粗)率仍位居各病之首,高于腫瘤和其他疾病,嚴(yán)重?fù)p害了人民大眾的身心健康。冠心病常規(guī)的治療方法有藥物治療和手術(shù)治療,其中經(jīng)皮冠脈介入術(shù)(PCI)作為治療方法之一,因見(jiàn)效快,療效明確,受到大家一致的關(guān)注。但PCI仍然有很多問(wèn)題不能解決,如PCI術(shù)后再狹窄,術(shù)后生活質(zhì)量未改善,心理狀態(tài)不平穩(wěn),心絞痛的復(fù)發(fā)等等,這些問(wèn)題困擾著廣大醫(yī)師和患者。祖國(guó)醫(yī)學(xué)中沒(méi)有冠心病、PCI術(shù)后胸痛等名詞,根據(jù)其臨床癥狀和表現(xiàn),類似于中醫(yī)名詞"胸痹心痛"所指范疇。中醫(yī)的內(nèi)治法和外治法在幾千年的使用中挽救了無(wú)數(shù)人的生命。如今西醫(yī)在臨床上也面臨很多棘手甚至不能解決的問(wèn)題,中醫(yī)一直倡導(dǎo)辨證論治,始終提倡把人作為一個(gè)整體,因此在很多治療方面可以很好的發(fā)揮其優(yōu)勢(shì),和西醫(yī)學(xué)結(jié)合起來(lái),取長(zhǎng)補(bǔ)短,以減輕患者的病痛。目的一:對(duì)160例行PCI術(shù)的且中醫(yī)辨證為氣虛痰瘀的不穩(wěn)定型心絞痛患者進(jìn)行研究,以觀察芪參益氣滴丸聯(lián)合心脈通貼散對(duì)冠心病PCI術(shù)后氣虛痰瘀型患者臨床療效。方法:選擇160例行PCI術(shù)的冠心病不穩(wěn)定型心絞痛患者,采用隨機(jī)數(shù)字表法分為對(duì)照組和治療組(A、B、C組),每組40例,四組均采用常規(guī)西藥治療,治療A組在對(duì)照組治療基礎(chǔ)上加用心脈通貼散;治療B組在對(duì)照組治療基礎(chǔ)上加用芪參益氣滴丸;C組在對(duì)照組治療基礎(chǔ)上加用芪參益氣滴丸1包3次/日及心脈通貼散穴位貼敷。療程共4周。觀察臨床療效、中醫(yī)癥候積分、凝血功能(PT、APTT、TT、FIB)、Hs-CRP、MPO、血脂(TC、LDL、LPA)和FFA等的變化。結(jié)果:1.四組心絞痛療效和中醫(yī)證候療效均有一定的改善,而治療組的總有效率高于對(duì)照組,尤其是顯效率更是明顯,四組比較有顯著性差異(P0.05),治療C組療效最佳。2.四組生活質(zhì)量均有改善,其中四組治療前后比較心絞痛穩(wěn)定狀態(tài)(AS)、心絞痛發(fā)作情況(AF)、治療滿意程度(TS)和疾病認(rèn)知程度(DP)均有不同程度改善(P0.05,P0.01),而治療組在治療后AS、AF、TS、DP優(yōu)于同期對(duì)照組(P0.05),且C組優(yōu)于A組、B組(P0.05)。四組治療后心電圖及動(dòng)態(tài)心電圖較治療前改善,其中治療組優(yōu)于對(duì)照組。四組治療后左室大小無(wú)明顯差異,但治療組射血分?jǐn)?shù)優(yōu)于對(duì)照組。3.四組凝血功能均有改善,其中四組治療前后比較凝血酶原時(shí)間(PT)、活化部分凝血活酶時(shí)間(APTT)、凝血酶時(shí)間(TT)均有不同程度延長(zhǎng),但治療前后無(wú)明顯差異(P0.05);四組治療前后纖維蛋白原(FIB)均有明顯改善,有不同程度下降,而治療組在治療后優(yōu)于同期對(duì)照組(P0.05),且C組優(yōu)于A組、B組(P0.05)。4.四組患者治療前后血Hs-CRP和MPO水平均有不同程度降低(P0.05)。四組治療后比較,治療組血Hs-CRP和MPO水平明顯低于對(duì)照組(P0.05),且C組優(yōu)于A組、B組(P0.05)。四組在治療后比較,中西醫(yī)聯(lián)合治療后膽固醇(TC)、低密度脂蛋白(LDL)、脂蛋白a(LPA)、游離脂肪酸(FFA)的降幅也略優(yōu)于對(duì)照組。結(jié)論:心脈通貼散和芪參益氣滴丸不但具有改善不穩(wěn)定型心絞痛患者PCI術(shù)后的心絞痛療效及中醫(yī)癥候的作用,還具有改善凝血功能,降低血脂及不穩(wěn)定斑塊炎癥因子水平(Hs-CRP、MPO),提高患者生活質(zhì)量的作用。提示芪參益氣滴丸、心脈通貼散是防治不穩(wěn)定型心絞痛疾病的有效藥物,具有穩(wěn)定不穩(wěn)定性斑塊及抗炎的作用。其不良反應(yīng)少,值得臨床推廣。目的二:探討芪參益氣滴丸聯(lián)合心脈通貼散對(duì)缺血再灌注損傷大鼠的心功能、血流動(dòng)力學(xué)、炎癥因子的影響。方法:對(duì)大鼠行冠脈結(jié)扎,繼則松開(kāi)結(jié)扎線,使大鼠形成缺血再灌注損傷,然后分組予芪參益氣滴丸聯(lián)和心脈通貼散以及阿托伐他汀鈣治療4周。最后分別監(jiān)測(cè)各組的心臟彩超、血流動(dòng)力學(xué)、心肌HE染色、NT-proBNP、CKMB、cTnI及炎癥因子Hs-CRP、MPO。結(jié)果:1.與模型組比較,芪參益氣滴丸聯(lián)合心脈通貼散組和阿托伐他汀組大鼠LVEDD、LVESD不同程度降低(P0.05),EF、FS及SV增加(P0.05)。2.與模型組比較,阿托伐他汀組和芪參益氣滴丸聯(lián)合心脈通貼散組大鼠MAP、LVDP、+dp/dtmax、-dp/dtmax顯著升高(P0.05),LVEDP及ST顯著降低(P0.05)。3.與假手術(shù)組比較,模型組、芪參益氣滴丸聯(lián)合心脈通貼散組和阿托伐他汀組血清NT-proBNP、Hs-CRP、MPO含量均明顯升高(P0.01)。與模型組比較,芪參益氣滴丸聯(lián)合心脈通貼散組和阿托伐他汀組血清NT-proBNP及Hs-CRP、MPO含量顯著性降低(P0.05)。
[Abstract]:Coronary heart disease (CHD) is a common disease in clinic. The mortality rate is increasing in recent years. In 2014, the death rate of cardiovascular disease in China is still the first in all diseases. It is higher than tumor and other diseases, which seriously damage the people's physical and mental health. The conventional treatment methods of coronary heart disease include drug treatment and surgical treatment, including percutaneous coronary intervention. PCI is one of the treatment methods, because of its quick effect and clear curative effect. But PCI still has many problems that can not be solved, such as restenosis after PCI, the quality of life is not improved after the operation, the mental state is not flat, the recurrence of angina pectoris, and so on. These problems have plagued the general doctors and patients. There is no coronal heart in Chinese medicine. Nouns such as disease and chest pain after PCI, according to their clinical symptoms and manifestations, are similar to the category of the Chinese medicine noun "chest pain and heart pain". The internal treatment and external treatment of traditional Chinese medicine have saved countless lives for thousands of years. Nowadays, western medicine is also faced with many difficult and incapable problems in clinical. Traditional Chinese medicine has always advocated syndrome differentiation and treatment. In the end, we advocate taking people as a whole, so they can give full play to their advantages in a lot of treatment, and combine with western medicine to relieve the pain of the patients. Objective: To study 160 cases of unstable angina pectoris with Qi deficiency and phlegm stasis in 160 cases, and to observe the combination of Qi Shen Yiqi dropping pills and heart pulse. The clinical effect of Tong tie powder on patients with Qi deficiency and phlegm stasis after PCI operation. Methods: 160 patients with unstable angina pectoris with PCI were selected and divided into control group and treatment group (A, B, C group), 40 cases in each group. The four groups were treated with conventional western medicine, and the A group was treated with the treatment of the control group. The treatment group B was treated with Qi Shen Yiqi dripping pill on the basis of the control group; group C was treated with 1 packs of Qi Shen Yiqi dropping pill 3 times / day and Xin Mai Tong pasting Acupoint Application on the basis of the control group. The clinical curative effect, TCM syndrome score, coagulation function (PT, APTT, TT, FIB), Hs-CRP, MPO, lipid (TC, LDL, LPA) and FFA and other changes were observed. Results: 1. The effect of four groups of angina pectoris and TCM syndrome were improved, and the total effective rate of the treatment group was higher than that of the control group, especially in the four groups (P0.05). The best quality of life of.2. four groups in the treatment group C was improved, of which four groups were compared with the stable state of angina pectoris (AS), angina pectoris before and after treatment. Seizures (AF), treatment satisfaction (TS) and disease cognition (DP) were improved (P0.05, P0.01) in different degrees (P0.05, P0.01), while AS, AF, TS, DP in the treatment group were better than those of the same group (P0.05) after treatment, and the C group was better than the A group. The four groups were better than the treatment group before treatment, and the treatment group was superior to the control group. The treatment group was better than the control group. There was no significant difference in the size of left ventricle after treatment, but the ejection fraction of the treatment group was better than that of the control group.3. four. Among the four groups, the prothrombin time (PT), the activated partial thromboplastin time (APTT) and the thrombin time (TT) were prolonged in different degrees, but there was no significant difference before and after treatment (P0.05); the four groups were treated before and after treatment. The fibrinogen (FIB) was obviously improved, and the treatment group was better than the control group (P0.05) after treatment, and the C group was better than the A group. The level of Hs-CRP and MPO in the group of group B (P0.05).4. four were reduced in varying degrees (P0.05). The four groups were compared with the control group. .05), and group C was superior to group A and group B (P0.05). The four groups were compared after treatment, and the decrease of cholesterol (TC), low density lipoprotein (LDL), lipoprotein a (LPA), and free fatty acid (FFA) was slightly better than that of the control group after the combination of Chinese and Western medicine. Conclusion: Xin Mai Tong paste and Qi Shen Yiqi dropping pills not only have angina pectoris after PCI operation in patients with unstable angina pectoris. The effect of curative effect and TCM syndrome also have the effect of improving the function of blood clotting, reducing the level of lipid and unstable plaque inflammatory factors (Hs-CRP, MPO), and improving the quality of life of the patients. It suggests that the Qi Shen Yiqi dropping pill is an effective drug to prevent and cure unstable angina pectoris, and it has the effect of stabilizing unstable plaque and anti inflammation. Objective two: To explore the effect of Qi Shen Yiqi dropping pill combined with Xin Mai Tong paste on the cardiac function, hemodynamics and inflammatory factors in rats with ischemia-reperfusion injury. Methods: the rats were ligated with coronary artery, then the ligation line was released to make the rats form the ischemia reperfusion injury, and then group to the Qi Shen Yiqi dropping pill. The treatment of cardiac color Doppler and atorvastatin calcium for 4 weeks. Finally, the cardiac color Doppler ultrasound, hemodynamics, myocardial HE staining, NT-proBNP, CKMB, cTnI and inflammatory factors Hs-CRP, MPO. results were measured respectively. 1. compared with the model group, Qi Shen Yiqi dropping pills combined with the heart Mai Tong paste group and atorvastatin group LVEDD, LVESD decreased in varying degrees (P0.). 05), EF, FS and SV increase (P0.05).2. compared with the model group, the Atorvastatin group and the Qi Shen Yiqi dropping pill combined with the heart Mai Tong paste group, the MAP, LVDP, +dp/dtmax, -dp/dtmax significantly increased (P0.05), LVEDP and ST significantly decreased, the model group, the Qi Shen Yiqi dropping pill combined with the heart Mai Tong paste group and the Atorvastatin group serum The content of NT-proBNP, Hs-CRP and MPO increased significantly (P0.01). Compared with the model group, the content of NT-proBNP and Hs-CRP in the serum of Qi Shen Yiqi dropping pills and the Atorvastatin group was significantly lower than that of the model group (P0.05).
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 黃體忠,黃泰康;中藥滴丸的制備與發(fā)展[J];中藥通報(bào);1985年04期

2 薛舒;不想換腦?就用舒腦欣滴丸[J];開(kāi)卷有益(求醫(yī)問(wèn)藥);2005年11期

3 吳青業(yè),金偉軍,陳志良;清痛滴丸的研制及臨床應(yīng)用[J];中國(guó)中醫(yī)藥科技;2000年01期

4 伍毅;吳金美;;復(fù)方田七滴丸質(zhì)量標(biāo)準(zhǔn)的研究[J];江西中醫(yī)學(xué)院學(xué)報(bào);2006年05期

5 尹志萍;趙德運(yùn);張古英;陳建軍;;兒茶滴丸的制備及質(zhì)量控制[J];河北醫(yī)藥;2008年08期

6 李忠瑞;張琦紅;羅敏;陳鵬;林玲;馬劍茵;;一種新的中藥滴丸制備方法(簡(jiǎn)報(bào))[J];中國(guó)民族民間醫(yī)藥;2010年14期

7 曾德惠;;滴丸的進(jìn)展[J];中國(guó)藥學(xué)雜志;1979年10期

8 曾德惠;;滴丸制備理論的綜述[J];中國(guó)藥學(xué)雜志;1981年05期

9 張震亞;暴國(guó)禎;;滴丸包裝機(jī)[J];醫(yī)藥工業(yè);1983年03期

10 趙仁泰;制備滴丸的簡(jiǎn)易設(shè)備[J];中國(guó)醫(yī)院藥學(xué)雜志;1984年11期

相關(guān)會(huì)議論文 前10條

1 李立宇;林展增;;治咳川貝枇杷滴丸不同劑量治療咳嗽的療效觀察[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國(guó)呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

2 黃海寬;邵秀麗;張?jiān)其h;;中藥滴丸生產(chǎn)仿真平臺(tái)的研究與設(shè)計(jì)實(shí)現(xiàn)[A];中國(guó)企業(yè)運(yùn)籌學(xué)學(xué)術(shù)交流大會(huì)論文集[C];2005年

3 李楠;肖凡;;治咳川貝枇杷滴丸對(duì)不同類型咳嗽患者的療效[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國(guó)呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

4 章臣桂;;中藥滴丸制劑研究及輔料應(yīng)用[A];第二屆全國(guó)藥用新輔料與中藥制劑新技術(shù)應(yīng)用研討會(huì)會(huì)議論文匯編[C];2005年

5 傅俊曾;宋生有;邢璐;姜民;彭佳敏;羅國(guó)安;白鋼;;液質(zhì)聯(lián)用法測(cè)定芪參益氣滴丸中2種人參皂苷的含量[A];第十屆全國(guó)藥用植物及植物藥學(xué)術(shù)研討會(huì)論文摘要集[C];2011年

6 劉結(jié)根;;芪參益氣滴丸治療肺心病心肺功能不全的研究[A];第十次中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)心血管病學(xué)術(shù)大會(huì)暨第五次江西省中西醫(yī)結(jié)合學(xué)會(huì)心血管病學(xué)術(shù)大會(huì)論文匯編[C];2010年

7 劉艷杰;董林毅;王利強(qiáng);程斌峰;侯媛媛;白鋼;;GC/MS法測(cè)定川貝枇杷滴丸中的揮發(fā)性成分[A];第十屆全國(guó)藥用植物及植物藥學(xué)術(shù)研討會(huì)論文摘要集[C];2011年

8 胡金芳;申秀萍;劉靜;梅學(xué)仁;;藿香正氣滴丸對(duì)胃腸功能的影響[A];中國(guó)藥學(xué)會(huì)應(yīng)用藥理專業(yè)委員會(huì)第三屆學(xué)術(shù)會(huì)議、中國(guó)藥理學(xué)會(huì)制藥工業(yè)專業(yè)委員會(huì)第十三屆學(xué)術(shù)會(huì)議暨2008生物醫(yī)藥學(xué)術(shù)論壇論文匯編[C];2008年

9 余暉;唐波;張藝凡;薛飛;;參附滴丸抗慢性心力衰竭模型試驗(yàn)實(shí)驗(yàn)研究[A];中華中醫(yī)藥學(xué)會(huì)中藥實(shí)驗(yàn)藥理分會(huì)第六屆學(xué)術(shù)會(huì)議論文匯編[C];2006年

10 謝華文;肖桂祥;康勇;郭冬秀;;芪參益氣滴丸治療氣虛血瘀型快速型心律失常臨床觀察[A];江西省第四次中西醫(yī)結(jié)合心血管學(xué)術(shù)交流會(huì)論文集[C];2008年

相關(guān)重要報(bào)紙文章 前10條

1 胡文華;中藥滴丸能否成為市場(chǎng)新寵[N];中國(guó)醫(yī)藥報(bào);2004年

2 徐淑森;中藥滴丸優(yōu)點(diǎn)多[N];醫(yī)藥養(yǎng)生保健報(bào);2005年

3 孫國(guó)強(qiáng);創(chuàng)新滴制技術(shù) 增加滴丸類型[N];中國(guó)中醫(yī)藥報(bào);2006年

4 德承;小滴丸大學(xué)問(wèn)[N];上海中醫(yī)藥報(bào);2008年

5 李玉峰;“中國(guó)第一滴丸”揚(yáng)名世界[N];天津日?qǐng)?bào);2006年

6 汪瑩;天津第六中藥廠：國(guó)內(nèi)首創(chuàng)現(xiàn)代化中藥滴丸制劑[N];中國(guó)工業(yè)報(bào);2007年

7 孫國(guó)強(qiáng);滴丸機(jī)冷卻柱溫度梯度控制的方法[N];中國(guó)中醫(yī)藥報(bào);2006年

8 ;滴丸——爭(zhēng)領(lǐng)現(xiàn)代劑型之風(fēng)騷[N];中國(guó)醫(yī)藥報(bào);2004年

9 孫國(guó)強(qiáng);滴丸機(jī)冷卻介質(zhì)的處理方法[N];中國(guó)中醫(yī)藥報(bào);2006年

10 阿龍;六味地黃滴丸健康5A標(biāo)準(zhǔn)[N];上海中醫(yī)藥報(bào);2008年

相關(guān)博士學(xué)位論文 前7條

1 彭彥卿;軟膠囊滴丸制藥生產(chǎn)過(guò)程的建模與優(yōu)化控制研究[D];廈門大學(xué);2009年

2 董林毅;治咳川貝枇杷滴丸藥效物質(zhì)組學(xué)及作用機(jī)制的評(píng)價(jià)研究[D];天津大學(xué);2012年

3 韓育明;鵝冰舒冠滴丸對(duì)血管內(nèi)皮細(xì)胞脂質(zhì)過(guò)氧化損傷保護(hù)作用研究[D];湖南中醫(yī)藥大學(xué);2005年

4 王建湘;舒冠滴丸對(duì)AS兔炎癥介質(zhì)的調(diào)節(jié)作用及治療不穩(wěn)定性心絞痛的臨床研究[D];湖南中醫(yī)學(xué)院;2004年

5 鄒迪;三苦滴丸對(duì)實(shí)驗(yàn)性大鼠心肌缺血的保護(hù)作用及炎癥機(jī)制的研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2012年

6 韓振蘊(yùn);清腦滴丸治療腔隙性腦梗死的臨床觀察及對(duì)腦缺血MARCKS磷酸化的調(diào)節(jié)　[D];北京中醫(yī)藥大學(xué);2004年

7 燕芳芳;芪參益氣滴丸對(duì)心肌梗死二級(jí)預(yù)防的作用及其機(jī)制研究[D];山東大學(xué);2008年

相關(guān)碩士學(xué)位論文 前10條

1 左璨粲;芪參益氣滴丸治療急性心肌梗死PCI術(shù)后患者的療效與安全性[D];暨南大學(xué);2015年

2 唐宜軒;雙去甲氧基姜黃素的分離純化及其滴丸制備工藝研究[D];成都中醫(yī)藥大學(xué);2016年

3 李明;滴丸缺陷檢測(cè)剔除設(shè)備研究[D];華中科技大學(xué);2015年

4 黃望平;滴丸硬度自動(dòng)檢測(cè)測(cè)控系統(tǒng)設(shè)計(jì)[D];華中科技大學(xué);2015年

5 任瑩利;治咳川貝枇杷滴丸抗病毒和細(xì)菌的實(shí)驗(yàn)研究[D];天津醫(yī)科大學(xué);2012年

6 蔣永莉;麝香通心滴丸對(duì)穩(wěn)定型心絞痛（痰熱瘀阻型）患者中醫(yī)證候影響的研究[D];黑龍江中醫(yī)藥大學(xué);2017年

7 陳晶晶;麝香通心滴丸對(duì)穩(wěn)定型心絞痛（痰熱瘀阻型）患者及AS模型大鼠Lp-PL-A2的影響[D];黑龍江中醫(yī)藥大學(xué);2017年

8 梁榮輝;頭痛寧滴丸藥理作用的研究[D];吉林農(nóng)業(yè)大學(xué);2004年

9 張江華;人參強(qiáng)心滴丸對(duì)充血性心力衰竭的實(shí)驗(yàn)研究[D];河北醫(yī)科大學(xué);2002年

10 詹珂;芎冰滴丸的藥學(xué)研究[D];成都中醫(yī)藥大學(xué);2007年

，

本文編號(hào)：2044818